Clinically Relevant Concentrations of Beta2-adrenergic Agonists Stimulate Maximal Cyclic Adenosine Monophosphate-dependent Airspace Fluid Clearance and Decrease Pulmonary Edema in Experimental Acid-induced Lung Injury
Overview
Emergency Medicine
Affiliations
Objective: To determine whether clinically relevant airspace concentrations of beta2-adrenergic agonists stimulated maximal alveolar fluid clearance rates and to determine whether beta2 agonist therapy decreased pulmonary edema in experimental acute lung injury.
Design: Prospective randomized laboratory investigation.
Setting: University-affiliated laboratory.
Subjects: Sprague Dawley rats.
Interventions: Dibutyryl cyclic adenosine monophosphate (cAMP), salmeterol, albuterol, and isoproterenol in normal rat lung. Salmeterol in a rat model of acid-induced lung injury.
Measurements And Main Results: Basal alveolar fluid clearance was 7.6 +/- 2.2 %/hr. Maximal cAMP-dependent alveolar fluid clearance rate was 32.9 +/- 10.9 %/hr (p <.05). Racemic albuterol 10(-5) M, salmeterol 10(-6) M, and isoproterenol 10(-6) M each stimulated alveolar fluid clearance to a level comparable to maximal cAMP-dependent alveolar fluid clearance. Compared with basal rates, alveolar fluid clearance was increased by both racemic albuterol 10(-6) M (14.5 +/- 3.0%, p <.05) and R-enantiomer 10(-6) M (15.0 +/- 4.6%, p <.05), but there was no difference between the two groups. Intra-alveolar salmeterol 10 (-6) M attenuated the degree of pulmonary edema following acid-induced lung injury. Extravascular lung water increased to only 180 +/- 30 microL with salmeterol treatment, compared with 296 +/- 65 microL in saline-treated rats 4 hrs after acid injury (p <.05). This decrease in lung water was accompanied by a 2.4-fold increase in the rate of alveolar fluid clearance at 4 hrs in the salmeterol-treated group. Lung endothelial permeability, expressed as extravascular plasma equivalents, was reduced to 64 +/- 9 microL with salmeterol compared with 119 +/- 51 microL in saline-treated rats 4 hrs after acid injury (p <.05).
Conclusions: Clinically relevant airspace concentrations of beta2-adrenergic agonists a) stimulate maximal cAMP-dependent airspace fluid clearance in normal lungs and b) reduce pulmonary edema in acid aspiration-induced lung injury by increasing alveolar fluid clearance and decreasing endothelial permeability. Clinical studies are required to determine whether beta2-adrenergic agonists improve outcome in patients with acute lung injury.
Zeng S, Nishihama M, Weldemichael L, Lozier H, Gold W, Arjomandi M BMC Pulm Med. 2024; 24(1):44.
PMID: 38245665 PMC: 10799390. DOI: 10.1186/s12890-023-02808-7.
Cong Z, Yang C, Zeng Z, Wu C, Zhao F, Shen Z Front Immunol. 2023; 13:1090773.
PMID: 36685596 PMC: 9853445. DOI: 10.3389/fimmu.2022.1090773.
Rich T, Leavesley S, Brandon A, Evans C, Raju S, Wagener B FASEB J. 2021; 35(10):e21946.
PMID: 34555226 PMC: 8483573. DOI: 10.1096/fj.202002712RR.
Future Trends in Nebulized Therapies for Pulmonary Disease.
McCarthy S, Gonzalez H, Higgins B J Pers Med. 2020; 10(2).
PMID: 32397615 PMC: 7354528. DOI: 10.3390/jpm10020037.
Ashoor T, Hasseb A, Esmat I Korean J Anesthesiol. 2020; 73(6):509-517.
PMID: 32106642 PMC: 7714627. DOI: 10.4097/kja.19418.